Journal
MBIO
Volume 6, Issue 1, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/mBio.02227-14
Keywords
-
Categories
Funding
- Defense Threat Reduction Agency
- NIAID [HHSN272200700016I]
- National Science Foundation Graduate research fellowship [DGE 1144152]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM080177] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Until recently, Ebola virus (EBOV) was a rarely encountered human pathogen that caused disease among small populations with extraordinarily high lethality. At the end of 2013, EBOV initiated an unprecedented disease outbreak in West Africa that is still ongoing and has already caused thousands of deaths. Recent studies revealed the genomic changes this particular EBOV variant undergoes over time during human-to-human transmission. Here we highlight the genomic changes that might negatively impact the efficacy of currently available EBOV sequence-based candidate therapeutics, such as small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and antibodies. Ten of the observed mutations modify the sequence of the binding sites of monoclonal antibody (MAb) 13F6, MAb 1H3, MAb 6D8, MAb 13C6, and siRNA EK-1, VP24, and VP35 targets and might influence the binding efficacy of the sequence-based therapeutics, suggesting that their efficacy should be reevaluated against the currently circulating strain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available